Runhui Wu

1.9k total citations · 1 hit paper
145 papers, 1.1k citations indexed

About

Runhui Wu is a scholar working on Hematology, Genetics and Immunology. According to data from OpenAlex, Runhui Wu has authored 145 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 129 papers in Hematology, 36 papers in Genetics and 19 papers in Immunology. Recurrent topics in Runhui Wu's work include Platelet Disorders and Treatments (81 papers), Hemophilia Treatment and Research (70 papers) and Blood groups and transfusion (38 papers). Runhui Wu is often cited by papers focused on Platelet Disorders and Treatments (81 papers), Hemophilia Treatment and Research (70 papers) and Blood groups and transfusion (38 papers). Runhui Wu collaborates with scholars based in China, Canada and United States. Runhui Wu's co-authors include Zhenping Chen, K. H. Luke, Jing Sun, Hao Gu, Man‐Chiu Poon, Xinyi Wu, Xiaoling Cheng, Yan Su, Francesco Rodeghiero and Meera Chitlur and has published in prestigious journals such as The Lancet, Blood and IEEE Access.

In The Last Decade

Runhui Wu

127 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial

2023 67 citations Runhui Wu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Runhui Wu China	16	921	174	148	101	85	145	1.1k
Carolyn M. Bennett United States	18	782 0.8×	180 1.0×	65 0.4×	153 1.5×	142 1.7×	48	983
Man Updesh Singh Sachdeva India	13	245 0.3×	185 1.1×	107 0.7×	126 1.2×	28 0.3×	118	648
Gavivann Veerakul Thailand	14	238 0.3×	163 0.9×	177 1.2×	61 0.6×	48 0.6×	34	744
Kyung‐Nam Koh South Korea	14	297 0.3×	91 0.5×	60 0.4×	166 1.6×	31 0.4×	89	660
Massimiliano Postorino Italy	16	626 0.7×	194 1.1×	251 1.7×	84 0.8×	15 0.2×	39	924
Antônio Vaz de Macedo Brazil	12	608 0.7×	167 1.0×	214 1.4×	83 0.8×	18 0.2×	38	757
Stephanie von Harsdorf Germany	16	446 0.5×	108 0.6×	91 0.6×	310 3.1×	87 1.0×	35	947
ZiYi Lim United Kingdom	10	633 0.7×	194 1.1×	158 1.1×	181 1.8×	49 0.6×	28	784
Jane Apperley United Kingdom	14	845 0.9×	256 1.5×	64 0.4×	352 3.5×	35 0.4×	28	1.1k
Lydia Jones United Kingdom	11	749 0.8×	255 1.5×	59 0.4×	268 2.7×	59 0.7×	27	922

Countries citing papers authored by Runhui Wu

Since Specialization

Citations

This map shows the geographic impact of Runhui Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Runhui Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Runhui Wu more than expected).

Fields of papers citing papers by Runhui Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Runhui Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Runhui Wu. The network helps show where Runhui Wu may publish in the future.

Co-authorship network of co-authors of Runhui Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Runhui Wu. A scholar is included among the top collaborators of Runhui Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Runhui Wu. Runhui Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Nan, et al.. (2025). The impact of Mycoplasma pneumoniae infection on platelets in children with immune thrombocytopenia: a real-world study from China. Annals of Hematology. 104(1). 105–110.

Gu, Hao, et al.. (2024). HIF-1α induced by hypoxic condition regulates Treg/Th17 axis polarization in chronic immune thrombocytopenia. International Immunopharmacology. 131. 111810–111810. 7 indexed citations

Wu, Runhui, et al.. (2024). Therapeutic Potential of Roxadustat in Immune Thrombocytopenia: A Mendelian Randomization Analysis. Blood. 144(Supplement 1). 5415–5415. 1 indexed citations

Chen, Zhenping, Guoqing Liu, Gang Li, et al.. (2024). Real‐world use of emicizumab in Chinese children with hemophilia A: Retrospective data from a comprehensive care center. Pediatric Investigation. 8(4). 244–252.

Rezende, Suely Meireles, Ignacio Neumann, Pantep Angchaisuksiri, et al.. (2024). International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology. Journal of Thrombosis and Haemostasis. 22(9). 2629–2652. 13 indexed citations

Wang, Zhifa, et al.. (2024). The early and rapid response to daratumumab in children with chronic refractory immune thrombocytopenia from a referral single centre of China. British Journal of Haematology. 205(1). 300–305. 1 indexed citations

Li, Zekun, et al.. (2023). Early immune tolerance induction is a unique predictor of favorable outcomes in hemophilia A children with intron 22 inversion and high-responding inhibitors. Thrombosis Research. 226. 56–60.

Li, Yue, et al.. (2023). Oral health status and oral habits of children and adolescents with hemophilia: a report from the children’s hemophilia comprehensive care center of China. European Journal of Pediatrics. 183(2). 897–902. 2 indexed citations

Liang, Qian, et al.. (2023). Complete F9 Gene Deletion, Duplication, and Triplication Rearrangements: Implications for Factor IX Expression and Clinical Phenotypes. Thrombosis and Haemostasis. 124(4). 374–385. 2 indexed citations

10.

Hu, Huimin, Weiling Zhang, Yi Zhang, et al.. (2023). Individualized chemotherapy and efficacy analysis of hepatoblastoma in children. Pediatric Blood & Cancer. 71(1). e30693–e30693. 1 indexed citations

11.

Wang, Zhifa, et al.. (2023). Transient increase in platelet counts associated with COVID‐19 infection during TPO‐RA as the second‐line treatment in children with ITP. British Journal of Haematology. 203(3). 384–388. 2 indexed citations

12.

Wang, Zhifa, Nan Wang, Jingjing Liu, et al.. (2023). Long‐term eltrombopag in children with chronic immune thrombocytopenia: A single‐centre extended real‐life observational study in China. British Journal of Haematology. 204(3). 1017–1023. 3 indexed citations

13.

Li, Gang, et al.. (2022). Enhanced pharmacokinetics and reduced bleeds in boys with hemophilia A after switching to Kovaltry from other standard half‐life factor VIII concentrates. Research and Practice in Thrombosis and Haemostasis. 6(2). e12686–e12686. 3 indexed citations

14.

Cheng, Xiaoling, et al.. (2022). Effect of Wuzhi capsules on cyclosporine A concentration in children with aplastic anemia immunotherapy: a single-center observational study. Expert Review of Clinical Pharmacology. 15(3). 365–369. 1 indexed citations

15.

Li, Gang, Yan Wang, Ningning Zhang, et al.. (2022). Individualised prophylaxis based on personalised target trough FVIII level optimised clinical outcomes in paediatric patients with severe haemophilia A. Haemophilia. 28(6). e209–e218. 8 indexed citations

16.

Zhang, Wenhui, Man‐Chiu Poon, Runhui Wu, et al.. (2022). Factor IX inhibitors in haemophilia B: A report of National Haemophilia Registry in China. Haemophilia. 29(1). 123–134. 6 indexed citations

17.

Li, Zekun, Guoqing Liu, Zhenping Chen, et al.. (2022). Eradication of FIX inhibitor in haemophilia B children using low‐dose immune tolerance induction with rituximab‐based immunosuppressive agent(s) in China. Haemophilia. 28(4). 625–632. 3 indexed citations

18.

Cheng, Xiaoling, Lingling Fu, Zhenping Chen, et al.. (2021). Spotlight on eltrombopag in pediatric ITP in China: a long-term observational study in real-world practice. Blood Advances. 5(19). 3799–3806. 12 indexed citations

19.

Wu, Runhui, Xiaojing Li, Qing Zhang, et al.. (2021). Significant reduction in hemarthrosis in boys with severe hemophilia A: The China hemophilia individualized low‐dose secondary prophylaxis study. Research and Practice in Thrombosis and Haemostasis. 5(6). e12552–e12552. 8 indexed citations

20.

Li, Zekun, Zhenping Chen, Xiaoling Cheng, et al.. (2019). Low‐dose immune tolerance induction for children with hemophilia A with poor‐risk high‐titer inhibitors: A pilot study in China. Research and Practice in Thrombosis and Haemostasis. 3(4). 741–748. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact